Meeting Reports

Subcategories:EULAR/Other Other ACR meetings

The 2025 ACR Awards of Distinction

Patrice Fusillo | October 25, 2025

The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.

The 2025 ARP President’s & Merit Awards

Patrice Fusillo | October 25, 2025

Meet the 2025 ARP President’s & Merit Award recipients honored for their significant contributions to rheumatology research, education & patient care.

The ACR Names 16 New Masters

Patrice Fusillo | October 25, 2025

The ACR recognizes 16 members with its highest honor. See the 2025 class of ACR Masters & read their personal reflections on this career milestone.

ACR Honors Distinguished Fellows: Class of 2025

Patrice Fusillo | October 25, 2025

Meet the 10 clinical & research fellows named 2025 ACR Distinguished Fellows. Learn what this prestigious honor means to them & their work.

A Liquid Biopsy for Lupus Nephritis?

Samantha C. Shapiro, MD | October 10, 2025

Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.

Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?

Mithu Maheswaranathan, MD | September 9, 2025

A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.

10 Things to Know about Lupus

Mithu Maheswaranathan, MD | September 8, 2025

SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.

Sjögren’s Disease: More Than Just a Syndrome

Jason Liebowitz, MD, FACR | August 26, 2025

A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.

Promising Phase 2 Results for Efgartigimod alfa-fcab in Adults with Primary Sjögren’s Disease

Michele B. Kaufman, PharmD, BCGP | August 26, 2025

A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.

Preventive Strategies & Novel Treatments for RA

Jason Liebowitz, MD, FACR | August 25, 2025

Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.